Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 15 - Drugs for genital or sexual disorders; Contraceptives
Patents for A61P 15 - Drugs for genital or sexual disorders; Contraceptives (55,635)
05/2003
05/14/2003EP1309552A1 Compounds and inhibitors of phospholipases
05/14/2003EP1309544A1 Compounds acting as melanocortin receptor ligands
05/14/2003EP1309334A2 Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders
05/14/2003EP1309331A2 Medicine for fighting against sexual dysfunction
05/14/2003EP1309316A2 Oral fast-melt dosage form of a cyclooxygenase-2 inhibitor
05/14/2003EP1112266B1 Substituted 4-amino-2-aryl-pyrimidines, their production and use and pharmaceutical preparations containing same
05/14/2003EP0815255B1 Hormone and growth factor phosphoglycan mimetics from mycobacterium vaccae
05/14/2003CN1418216A Novel 2,3,4,5-tetrahydro-1H-[1,4] diazepino [1,7a]indole compound
05/14/2003CN1418214A 4-Hydroxy-1, 8-Naphthyridine-3-carboxamides as antiviral agents
05/14/2003CN1418194A Amide compounds and use thereof
05/14/2003CN1418192A Pharmaceutical compositions containing azetidine derivatives novel azetidine derivatives and preparation thereof
05/14/2003CN1418187A Carboxylic acid derivatives as IP antagonists
05/14/2003CN1418111A Novel Ligands and method for preparing same
05/14/2003CN1418107A Use of FSH for treating infertility
05/14/2003CN1418102A 激素替代疗法 Hormone replacement therapy
05/14/2003CN1418096A IL-8 receptor antagonists
05/14/2003CN1416878A Mastoproliferation treating medicine
05/14/2003CN1416861A Medicine composition with lactogenic function and its prepn
05/14/2003CN1416849A Externally applied medicine for treating mastopathy and its prepn
05/14/2003CN1416835A Chinese medicine prepn for treating male's sexual dysfunction systematically
05/14/2003CN1416830A Galactic medicine and its prepn
05/14/2003CN1416829A Blood-forming and menstruation-promoting capsule
05/13/2003US6562868 Method of treating female sexual dysfunction, comprising administering to a human a therapeutically effective and physiologically acceptable amount of a prostaglandin selected from the group consisting of 19-hydroxy-PGE2,
05/13/2003US6562857 Cyanopyrroles
05/13/2003US6562835 One morphinan selected from the group consisting of dextromethorphan, dextrorphan and at least one active agent selected from tricyclic antidepressants, antispasmodics, direct-acting bladder smooth muscle relaxants, and estrogens
05/13/2003US6562824 Dihydropyridine soft drugs, and related compositions and methods
05/13/2003US6562380 Methods for treating or reducing prediposition to breast cancer, pre-menstrual syndrome or symptoms associated with menopause by administration of phyto-estrogen
05/13/2003US6562336 Dietary or pharmaceutical composition for use for the prevention or treatment of hyperoxaluria
05/13/2003US6561976 Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug
05/09/2003CA2464707A1 Compositions for treatment of postmenopausal female sexual dysfunction
05/08/2003WO2003038068A1 Lactic acid producing bacteria for use as probiotic organisms in the human vagina
05/08/2003WO2003038043A2 Combinations of dr5 antibody and other therapeutic agents
05/08/2003WO2003037916A2 Linear basic compounds having nk-2 antagonist activity and formulations thereof
05/08/2003WO2003037905A1 Silicon compounds
05/08/2003WO2003037899A1 Pde9 inhibitors for treating cardiovascular disorders
05/08/2003WO2003037892A1 Compounds useful as reversible inhibitors of cysteine proteases
05/08/2003WO2003037887A1 Therapeutic isoquinoline compounds
05/08/2003WO2003037874A1 An efficient synthesis of 5-heteroatom-containing-pyrazoles
05/08/2003WO2003037873A1 Substituted benzo[b]azepin-2-one compounds
05/08/2003WO2003037872A1 Therapeutic quinoline compounds with 5-ht-antagonistic properties
05/08/2003WO2003037871A1 Therapeutic quinolone compounds with 5-ht-antagonistic properties
05/08/2003WO2003037847A1 Benzamide derivatives as antagonists of orexin receptors
05/08/2003WO2003037433A1 Co-cycloalkyl 17-heteroaryl prostaglandin e2 analogs as ep2-receptor agonists
05/08/2003WO2003037382A1 Low concentration of peroxide for treating or preventing vaginal infections
05/08/2003WO2003037381A1 Vaginally administerd anti-dysrhythmic agents for treating pelvic pain and infertility
05/08/2003WO2003037374A1 Method of treatment of vulval vestibulitis
05/08/2003WO2003037367A2 New bacterium causing poultry disease and vaccine derived thereof
05/08/2003WO2003037352A1 1-phenyl-5-n-heterocyclyl-pyrazoles as cyclooxygenase inhibitors for the treatment of inflammation associated disorders
05/08/2003WO2003037348A1 Antagonists of prostaglandin receptors ep2 and/or ep4 for the treatment of dysmenorrhea and menorrhagia
05/08/2003WO2003037336A1 1-(5-sulfonyl-pyridin-2-yl)-5-(methylidene-cycloalkylmethoxy)-1h-pyrazole-4-carbonitrile derivatives and other compounds as cyclooxygenase inhibitors for the treatment of arthritis, neurodegeneration and colon cancer
05/08/2003WO2003037335A1 5-heteroatom-substituted pyrazoles
05/08/2003WO2003037332A1 Phenyl substituted 5-membered nitrogen containing heterocycles for the treatment of obesity
05/08/2003WO2003037330A1 Sulfonyl-and sulfonylheteroaryl-pyrazoles with a hydrazinyl or nitrogen oxide substituent at the 5-position for use as cyclooxygenase inhibitors
05/08/2003WO2003037328A1 Oxindole hydrazide modulators of protein tyrosine phosphatases (ptps)
05/08/2003WO2003037322A1 Combination of an atp-competitive inhibitor of bcr/abl kinase activity and a tyrphostin analog
05/08/2003WO2003037320A1 Pharmaco-dietary preparation having a nutrition-supplementing and nutrition-enhancing effect
05/08/2003WO2003037268A2 Hepta-, octa- and nonapeptides having antiangiogenic activity
05/08/2003WO2003037266A2 Tetra-, penta-, hexa- and heptapeptides having antiangiogenic activity
05/08/2003WO2003023404A8 A method of diagnosis and treatment and agents useful for same
05/08/2003WO2003014322A3 Proteins associated with cell growth, differentiation, and death
05/08/2003WO2003012105A3 Vegf isoform
05/08/2003WO2002081499A3 Somatostatin agonists
05/08/2003WO2002028405A3 Method for inducing onset of the reproductive cycle of female breeding animals
05/08/2003WO2002026223A3 Catecholamine pharmaceutical compositions and methods
05/08/2003US20030088111 Protected forms of pharmacologically active agents and uses therefor
05/08/2003US20030087963 Methods of preparing and using 2-hydroxy derivatives of sibutramine and its metabolites
05/08/2003US20030087948 Phenylethylamines and condensed rings variants as prodrugs of catecholamines, and their use
05/08/2003US20030087919 Rho-kinase inhibitors
05/08/2003US20030087916 Pyrimidin-4-one compounds
05/08/2003US20030087901 Compounds and methods for modulation of estrogen receptors
05/08/2003US20030087898 Opioid receptor antagonists; treating irritable bowel syndrome, drug addiction or dependency, depression, and eating disorders.
05/08/2003US20030087897 Containing carboxylic acid groups; diagnosis; prophylaxis
05/08/2003US20030087886 Orally active androgens
05/08/2003US20030087816 Anticancer, antitumor agents; genetic engineering
05/08/2003US20030087801 Methods for treatment using novel ligands of the neuropeptide receptor hfgan72
05/08/2003US20030087375 Sperm specific proteins
05/08/2003US20030087307 Compound for use in the prevention and treatment of respiratory and nervous system disorders
05/08/2003US20030087306 Methods for identifying novel multimeric agents that modulate receptors
05/08/2003US20030087264 Detection of regulatory response to pulsatile electromagnetic stimulus; obtain tissue sample, insert probe, apply pulsatile stimulus, detect gene expression, classify genes which are expresed
05/08/2003US20030087252 Novel compositions and methods in cancer associated with altered expression of PRDM11
05/08/2003US20030086977 Forming a free- standing powder comprising at least one antimicrobial metal with atomic disorder; and injecting the free-standing powder in therapeutically effective amounts to the tissue which is to be treated
05/08/2003CA2466824A1 Pde9 inhibitors for treating cardiovascular disorders
05/08/2003CA2466152A1 Tetra-, penta-, hexa- and heptapeptides having antiangiogenic activity
05/08/2003CA2465350A1 Therapeutic quinoline compounds with 5-ht-antagonistic properties
05/08/2003CA2465344A1 Therapeutic quinolone compounds with 5-ht-antagonistic properties
05/08/2003CA2465314A1 Combinations of antibodies selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and other therapeutic agents
05/08/2003CA2464997A1 Silicon compounds
05/08/2003CA2464945A1 Pharmaco-dietary preparation having a nutrition-supplementing and nutrition-enhancing effect
05/08/2003CA2464944A1 An efficient synthesis of 5-heteroatom-containing-pyrazoles
05/08/2003CA2464353A1 Linear basic compounds having nk-2 antagonist activity and formulations thereof
05/08/2003CA2464342A1 Therapeutic isoquinoline compounds
05/08/2003CA2464191A1 Substituted benzo[b]azepin-2-one compounds
05/08/2003CA2463977A1 Method of treatment of vulval vestibulitis
05/08/2003CA2463770A1 Compounds useful as reversible inhibitors of cysteine proteases
05/08/2003CA2463441A1 Phenyl substituted 5-membered nitrogen containing heterocycles for the treatment of obesity
05/08/2003CA2462652A1 New bacterium causing poultry disease and vaccine derived thereof
05/08/2003CA2459178A1 Lactic acid producing bacteria for use as probiotic organisms in the human vagina
05/08/2003CA2426785A1 Co-cycloalkyl 17-heteroaryl prostaglandin e2 analogs as ep2-receptor agonists
05/07/2003EP1308446A1 5-(alkylidene-cycloalkyl)- and 5-(alkylidene-heterocyclyl)-pyrazoles
05/07/2003EP1308445A1 5-heteroatom-substituted pyrazoles
1 ... 361 362 363 364 365 366 367 368 369 370 371 372 373 374 375 376 377 378 379 380 381 ... 557